In the past few years, evidence has accumulated that abnormal expression or activation of CENPF is a common phenomenon in malignant tumors, and there is a significant correlation between CENPF and tumorigenesis or progression in cancer patients, including HCC 27, 28, prostate cancer, breast cancer 29, and other tumors 30, which has been partially confirmed. Here, CENPF is linked to prostate cancer.